JP2007510649A5 - - Google Patents

Download PDF

Info

Publication number
JP2007510649A5
JP2007510649A5 JP2006538342A JP2006538342A JP2007510649A5 JP 2007510649 A5 JP2007510649 A5 JP 2007510649A5 JP 2006538342 A JP2006538342 A JP 2006538342A JP 2006538342 A JP2006538342 A JP 2006538342A JP 2007510649 A5 JP2007510649 A5 JP 2007510649A5
Authority
JP
Japan
Prior art keywords
chlorophenyl
dichlorophenyl
oxo
alkyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006538342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007510649A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/036102 external-priority patent/WO2005047285A1/en
Publication of JP2007510649A publication Critical patent/JP2007510649A/ja
Publication of JP2007510649A5 publication Critical patent/JP2007510649A5/ja
Pending legal-status Critical Current

Links

JP2006538342A 2003-11-04 2004-10-29 置換ナフチリジノン誘導体 Pending JP2007510649A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51706003P 2003-11-04 2003-11-04
PCT/US2004/036102 WO2005047285A1 (en) 2003-11-04 2004-10-29 Substituted naphthyridinone derivatives

Publications (2)

Publication Number Publication Date
JP2007510649A JP2007510649A (ja) 2007-04-26
JP2007510649A5 true JP2007510649A5 (cg-RX-API-DMAC7.html) 2007-08-09

Family

ID=34590136

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538342A Pending JP2007510649A (ja) 2003-11-04 2004-10-29 置換ナフチリジノン誘導体

Country Status (9)

Country Link
US (1) US7728141B2 (cg-RX-API-DMAC7.html)
EP (1) EP1682550B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007510649A (cg-RX-API-DMAC7.html)
CN (1) CN1875021A (cg-RX-API-DMAC7.html)
AT (1) ATE452890T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004289638B2 (cg-RX-API-DMAC7.html)
CA (1) CA2544191A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004024814D1 (cg-RX-API-DMAC7.html)
WO (1) WO2005047285A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087880A2 (en) * 2003-03-26 2004-10-14 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008076427A2 (en) 2006-12-18 2008-06-26 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US8048892B2 (en) 2006-12-18 2011-11-01 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
TW200838516A (en) * 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
EP2139333A4 (en) * 2007-03-28 2010-11-10 Merck Sharp & Dohme SUBSTITUTED PYRID- [3,2-E] - [1,2,4] -TRIAZOL- [4,3-C] -PYRIMIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS
EP2142509B1 (en) 2007-04-18 2013-12-04 Amgen, Inc Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
CA2685219C (en) 2007-05-04 2012-06-19 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
DK2665741T3 (en) * 2011-01-10 2019-04-29 Invion Inc APPLICATION OF BETA-ADRENERGE INVERSE AGONISTS FOR SMOKE CLEANING
US20140256767A1 (en) 2011-10-31 2014-09-11 The Broad Institute, Inc. Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators
EP2781520B1 (en) * 2011-11-17 2016-05-04 Xuanzhu Pharma Co., Ltd. Three-ring pi3k and/or mtor inhibitor
CA3070073A1 (en) * 2017-07-18 2019-01-24 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
JP2020527588A (ja) 2017-07-18 2020-09-10 ニューベイション・バイオ・インコーポレイテッドNuvation Bio Inc. アデノシンアンタゴニストとしてのヘテロ環式化合物
CN113613655A (zh) * 2019-01-18 2021-11-05 诺维逊生物股份有限公司 化合物及其用途
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
KR20230041654A (ko) 2020-05-05 2023-03-24 테온 테라퓨틱스, 인크. 칸나비노이드 수용체 유형 2 (cb2) 조정제 및 그의 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
KR20010021696A (ko) 1997-07-11 2001-03-15 미즈노 마사루 퀴놀린 화합물 및 그의 의약용도
JP2000256323A (ja) * 1999-01-08 2000-09-19 Japan Tobacco Inc 2−オキソキノリン化合物及びその医薬用途
BR0212829A (pt) * 2001-09-26 2004-08-03 Bayer Pharmaceuticals Corp Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
CA2480800C (en) * 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005021547A2 (en) 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
MXPA06004043A (es) 2003-10-10 2006-06-28 Pfizer Prod Inc 2h-[1,2,4]triazolo[4,3-a]pirazinas sustituidas como inhibidores de la glucogeno sintetasa cinasa 3.
WO2005049615A1 (en) 2003-11-21 2005-06-02 Pfizer Products Inc. Pyrazolo`1,5-a!`1,3,5! triazin -4-one derivatives as cb1 receptor antagonists
WO2005061507A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyrazol-4-one cannabinoid receptor ligands and uses thereof
WO2005061505A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic imidazolyl pyrimidin-4-one cannabinoid receptor ligands and uses thereof
WO2005061504A1 (en) 2003-12-16 2005-07-07 Pfizer Products Inc. Bicyclic pyridazinone cannabinoid receptor ligands and uses thereof
HRP20070241T3 (hr) 2003-12-19 2007-07-31 Bristol-Myers Squibb Company Azabiciklički heterocikli kao modulatori kanabinoid receptora
US20060094714A1 (en) 2004-03-26 2006-05-04 Bayer Pharmaceuticals Corporation Compounds and their use to treat diabetes and related disorders
WO2005103052A1 (en) 2004-04-21 2005-11-03 Pfizer Products Inc. Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP7278359B2 (ja) Shp2の活性を阻害するための化合物および組成物
JP4180365B2 (ja) ピペラジン誘導体
US10975080B2 (en) Compounds and compositions for inhibiting the activity of SHP2
JP2012526735A5 (cg-RX-API-DMAC7.html)
JP2012526736A5 (cg-RX-API-DMAC7.html)
TW202104223A (zh) 磷脂醯肌醇3-激酶抑制劑
KR20010050223A (ko) Crf 길항제 및 관련 조성물의 용도
TW201014849A (en) 1,2-disubstituted heterocyclic compounds
TW201201811A (en) Heteroaryl imidazolone derivatives as JAK inhibitors
JP2008510006A5 (cg-RX-API-DMAC7.html)
JP2008534568A5 (cg-RX-API-DMAC7.html)
CN117486890A (zh) 三环类化合物及其用途
JP2022500466A (ja) 抗ウイルス剤としての官能化複素環
CZ20032044A3 (cs) Imidazolylové deriváty jako inhibitory faktoru uvolňujícího kortikotropin
JP2021506868A (ja) Pde1阻害剤としての大環状分子
WO2008024151A2 (en) Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use
KR20240134951A (ko) 트립타민 조성물 및 방법
CA2868228C (en) Treatment of respiratory depression
WO2010053127A1 (ja) α1GABAA受容体またはα5GABAA受容体の調整剤
JP2004509869A5 (cg-RX-API-DMAC7.html)
CN102202665A (zh) 包含毒蕈碱性受体拮抗剂和另一种活性成分的药物产品
HK40114766A (zh) 用於治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物
CN118632835A (zh) 色胺组合物和方法
HUP0300313A2 (hu) Vegyület, ezt tartalmazó gyógyszerkészítmény és alkalmazása fájdalom kezelésére
CN118434415A (zh) 用于治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物